Thailand vs Ukraine: Average cost of multi drug-resistant tuberculosis treatment
Thailand
1,823 constant 2022 US$
in 2024
Ukraine
1,994 constant 2022 US$
in 2024
Thailand rank
25th
Ukraine rank
24th
Average cost of multi drug-resistant tuberculosis treatment over time
- Thailand
- Ukraine
How they compare
Ukraine currently reports 1,994 constant 2022 US$ against 1,823 constant 2022 US$ in Thailand, a difference of 171 constant 2022 US$.
That makes Ukraine's figure about 1.1 times Thailand's.
The two have swapped places 3 times across 8 shared years of data; in 2017 it was Thailand ahead.
Thailand ranks 25th and Ukraine ranks 24th of 92 countries.
Thailand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Thailand | Ukraine | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 3,461 constant 2022 US$ | 1,731 constant 2022 US$ | 1,730 constant 2022 US$ | Thailand |
| 2020s | 2,196 constant 2022 US$ | 2,144 constant 2022 US$ | 51.4 constant 2022 US$ | Thailand |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Thailand or Ukraine?
- Ukraine, at 1,994 constant 2022 US$ against 1,823 constant 2022 US$ in Thailand as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Thailand and Ukraine?
- 171 constant 2022 US$, with Ukraine ahead.
- How many years of comparable data are there for Thailand and Ukraine?
- 8 years are reported by both, from 2017 to 2024.
- How do Thailand and Ukraine rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Thailand ranks 25th and Ukraine ranks 24th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.